Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company. It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products. The company was founded on October 1, 2013 and is... 
Sector
Pharmaceuticals
Calendar
11/04Earnings Release
Surperformance© rating of Actavis Inc
Trading Rating : Investor Rating :
More about the company
Financials ($)
Sales 2014 12 564 M
EBIT 2014 3 570 M
Net income 2014 1 571 M
Debt 2014 14 739 M
Yield 2014 -
Sales 2015 15 381 M
EBIT 2015 5 286 M
Net income 2015 2 520 M
Debt 2015 10 586 M
Yield 2015 -
PER 2014 40,15
PER 2015 20,44
EV / Sales 2014 6,10x
EV / Sales 2015 4,72x
Capitalization 61 937 M
More Financials
Latest news on ACTAVIS INC
6d ago ACTAVIS : FDA Advisory Committee Recommends Against Approval of Actavis' Nebivol..
09/05 ACTAVIS : Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, ..
09/02 ACTAVIS : Announces FDA Acceptance for Filing of NDA for Eluxadoline
08/26 ACTAVIS : to Present at Morgan Stanley Global Healthcare Conference 2014
08/22 ACTAVIS : Confirms Generic Neupro® Patent Challenge
08/21DJU.S. Restricts Narcotic Pain Drug Prescriptions
08/21DJDEA Restricts Narcotic Pain Drug Prescriptions
08/21 Pfizer back for AstraZeneca? Year-end move seen most likely
08/19 ACTAVIS : Announces Positive Topline Results From The Phase III Program Of Cefta..
08/05DJU.S. HOT STOCKS : Hot Stocks to Watch
07/30 AstraZeneca buys Almirall lung drugs for up to $2.1 billion
07/28 Pfizer's need for deal looms larger with earnings report
More news
Comments 
Advertisement
Income Statement Evolution
Actavis Inc : Income Statement Evolution
More Financials
EPS Revisions
Actavis Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF